• 1
    Johnson BE, Grayson J, Makuch RW, et al. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol. 1990; 8: 396401.
  • 2
    Albain KS, Crowley JJ, Livingston RB, et al. Long term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest. 1991; 99: 14251432.
  • 3
    Masutani M, Ochi Y, Kadota A, et al. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors? Oncol Rep. 2000; 7: 305310.
  • 4
    Murray N, Livinston R, Shepherd F, et al. Randomized study of CODE versus alternating CAV / PE for extensive stage small cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 1999; 17: 23002308.
  • 5
    Leyvraz S, Perey L, Rosti G, et al. Multiple courses of high dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgastrim for small cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1999; 17: 35313539.
  • 6
    Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol. 2002; 13: 539545.
  • 7
    Johnson BE, Fischer T, Fischer B, et al. Phase 2 study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003; 9: 58805887.
  • 8
    Chua YJ, Steer J, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev. 2004; 30: 521543.
  • 9
    Laurie SA, Logan D, Markman BR, et al. Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer. 2004; 43: 223240.
  • 10
    Einhorn LH, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol. 1988; 6: 451456.
  • 11
    Spiro SG, Souhami RG, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989; 59: 578583.
  • 12
    Johnson DH, Bass D, Einhorn LH, et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol. 1993; 11: 12231228.
  • 13
    Sculier JP, Berghmans T, Castaigne J, et al. Maintenance chemotherapy for small-call lung cancer: a critical review of the literature. Lung Cancer. 1998; 19: 141151.
  • 14
    Small cell lung cancer: treatment: limited-stage small cell lung cancer and extensive-stage small cell lung cancer, 2/1/ 2005 update.–6.
  • 15
    Minimum clinical recommendations for diagnosis, treatment and follow-up of small-cell lung cancer, 8/2003 update.
  • 16
    Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000; 18: 12201229.
  • 17
    Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for Stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. J Clin Oncol. 2004; 22: 33953407.
  • 18
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719748.
  • 19
    Thompson SG, Higgins JPT. Can meta-analysis help target interventions at individuals most likely to benefit? Lancet. 2005; 365: 341346.
  • 20
    Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet. 1999; 354: 18961900.
  • 21
    Hanna NH, Sandler AB, Loehrer PJ Sr, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002; 13: 95102.
  • 22
    Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-A Phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 21142122.
  • 23
    Beith JM, Clarke SJ, Woods RL, et al. Long-term follow-up of a randomized trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer. 1996; 32A: 438443.
  • 24
    Sculier JP, Paesmans M, Bureau G, et al. Randomized trial comparing induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. J Clin Oncol. 1996; 14: 23372344.
  • 25
    Cullen M, Morgan D, Gregory W, et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomized, controlled trial. Cancer Chemother Pharmacol. 1986; 17: 157160.
  • 26
    Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long term results of a randomized trial. J Clin Oncol. 1993; 11: 12301240.
  • 27
    Byrne MJ, van Hazel G, Trotter J, et al. Maintenance chemotherapy in limited small cell lung cancer: a randomized controlled trial. Br J Cancer. 1989; 60: 413418.
  • 28
    Ettinger DS, Finkelstein DM, Abeloff MD, et al. A randomized comparison of standard versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a Phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1990; 8: 230240.
  • 29
    Lebeau B, Chastang CI, Allard P, et al. Six vs. twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. Eur Respir J. 1992; 5: 286290.
  • 30
    Bleehen NM, Fayers PM, Girling DJ, et al. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer. 1989; 59: 584590.
  • 31
    Maurer LH, Tulloh M, Weiss RB, et al. A randomized combined modality trial in small cell carcinoma of the lung. Cancer. 1980; 45: 3039.
  • 32
    Bleehen NM, Girling DJ, Machin D, et al. A randomized trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I. Survival and prognostic factors. Br J Cancer. 1993; 68: 11501156.
  • 33
    Murren JR, Turrisi AT, Pass HI. Small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005. p 810843.
  • 34
    D'addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005; 23: 29262936.